Centogene
Centogene Regains Compliance with Nasdaq Listing Requirement
In December, the company was notified that its shares had failed to meet the Nasdaq's minimum bid price listing requirement.
Centogene Gets Nasdaq Non-Compliance Notice
The company has 180 days from the date of the notice to regain compliance with the listing requirement, during which time it will continue to trade on the exchange.
In Brief This Week: Centogene, T2 Biosystems, Labcorp, More
News items for the week of July 11, 2022.
Centogene Gets CE-IVD Mark for Cloud-Based Genetic Diagnostics Software Platform
CentoCloud provides clinical decision support for variant interpretation and enables laboratories to establish next-generation sequencing-based diagnostic testing.
In Brief This Week: Babson Diagnostics, HTG Molecular Diagnostics, Angle, Mainz Biomed, and More
News items for the in vitro diagnostics industry for the week of March 14, 2022.
Dec 16, 2020
Centogene Q3 Revenues Triple on COVID-19 Testing
Sep 23, 2020